JP2012528200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528200A5 JP2012528200A5 JP2012513314A JP2012513314A JP2012528200A5 JP 2012528200 A5 JP2012528200 A5 JP 2012528200A5 JP 2012513314 A JP2012513314 A JP 2012513314A JP 2012513314 A JP2012513314 A JP 2012513314A JP 2012528200 A5 JP2012528200 A5 JP 2012528200A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- particles
- metered dose
- dose inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 37
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 229940071648 metered dose inhaler Drugs 0.000 claims 17
- 239000013543 active substance Substances 0.000 claims 15
- 239000012190 activator Substances 0.000 claims 10
- 229960002848 formoterol Drugs 0.000 claims 10
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 10
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 7
- 229940015042 glycopyrrolate Drugs 0.000 claims 7
- 239000010419 fine particle Substances 0.000 claims 6
- 239000003380 propellant Substances 0.000 claims 6
- 239000000725 suspension Substances 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 230000003287 optical effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- 230000001133 acceleration Effects 0.000 claims 4
- 230000008695 pulmonary vasoconstriction Effects 0.000 claims 4
- 239000000443 aerosol Substances 0.000 claims 3
- KBHWKXNXTURZCD-UHFFFAOYSA-N 1-Methoxy-4-propylbenzene Chemical compound CCCC1=CC=C(OC)C=C1 KBHWKXNXTURZCD-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010061876 Obstruction Diseases 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 2
- 206010038687 Respiratory distress Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 239000000375 suspending agent Substances 0.000 claims 2
- BKLAJZNVMHLXAP-VKGMXUHCSA-N 3-[(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile Chemical compound C([C@H]1CC[C@@H](C2)[N+]1(C)C)C2CC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 BKLAJZNVMHLXAP-VKGMXUHCSA-N 0.000 claims 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960003060 bambuterol Drugs 0.000 claims 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims 1
- 229950010713 carmoterol Drugs 0.000 claims 1
- 229960001117 clenbuterol Drugs 0.000 claims 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims 1
- -1 dexpyronium Chemical compound 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229950001768 milveterol Drugs 0.000 claims 1
- BMKINZUHKYLSKI-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[[(2r)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 claims 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 1
- 229960001491 trospium Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18256509P | 2009-05-29 | 2009-05-29 | |
| US61/182,565 | 2009-05-29 | ||
| US25817209P | 2009-11-04 | 2009-11-04 | |
| US61/258,172 | 2009-11-04 | ||
| US30936510P | 2010-03-01 | 2010-03-01 | |
| US61/309,365 | 2010-03-01 | ||
| US34553610P | 2010-05-17 | 2010-05-17 | |
| US61/345,536 | 2010-05-17 | ||
| PCT/US2010/036659 WO2010138868A2 (en) | 2009-05-29 | 2010-05-28 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015199079A Division JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528200A JP2012528200A (ja) | 2012-11-12 |
| JP2012528200A5 true JP2012528200A5 (enExample) | 2013-07-18 |
| JP5823383B2 JP5823383B2 (ja) | 2015-11-25 |
Family
ID=42269864
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513314A Active JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2012513311A Active JP5873012B2 (ja) | 2009-05-29 | 2010-05-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2012513319A Active JP5873013B2 (ja) | 2009-05-29 | 2010-05-28 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015199079A Withdrawn JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513311A Active JP5873012B2 (ja) | 2009-05-29 | 2010-05-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2012513319A Active JP5873013B2 (ja) | 2009-05-29 | 2010-05-28 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015199079A Withdrawn JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Country Status (31)
| Country | Link |
|---|---|
| US (12) | US20110135737A1 (enExample) |
| EP (6) | EP2435025B1 (enExample) |
| JP (10) | JP5823383B2 (enExample) |
| KR (7) | KR101748892B1 (enExample) |
| CN (6) | CN107669664B (enExample) |
| AR (3) | AR076806A1 (enExample) |
| AU (3) | AU2010253770B9 (enExample) |
| BR (3) | BRPI1011229B8 (enExample) |
| CA (3) | CA2763941A1 (enExample) |
| CY (8) | CY1118040T1 (enExample) |
| DK (6) | DK3111927T3 (enExample) |
| ES (6) | ES2774367T3 (enExample) |
| FR (1) | FR19C1040I2 (enExample) |
| HR (6) | HRP20161098T1 (enExample) |
| HU (8) | HUE031229T2 (enExample) |
| IL (3) | IL216466B (enExample) |
| LT (8) | LT2435023T (enExample) |
| LU (2) | LUC00124I2 (enExample) |
| ME (1) | ME03631B (enExample) |
| MX (5) | MX393243B (enExample) |
| NL (1) | NL300995I2 (enExample) |
| NO (2) | NO2019026I1 (enExample) |
| PH (1) | PH12017500778A1 (enExample) |
| PL (6) | PL3106149T3 (enExample) |
| PT (6) | PT3106149T (enExample) |
| RU (5) | RU2016117972A (enExample) |
| SI (6) | SI3106149T1 (enExample) |
| SM (6) | SMT202000109T1 (enExample) |
| TW (9) | TWI792140B (enExample) |
| WO (3) | WO2010138868A2 (enExample) |
| ZA (4) | ZA201108275B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
| US10002325B2 (en) | 2005-03-30 | 2018-06-19 | Primal Fusion Inc. | Knowledge representation systems and methods incorporating inference rules |
| AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| DK1986679T3 (da) | 2006-02-22 | 2017-11-20 | Mannkind Corp | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof |
| CN103252007B (zh) | 2008-06-13 | 2016-06-22 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| TWI792140B (zh) * | 2009-05-29 | 2023-02-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
| RU2531455C2 (ru) * | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| US10474647B2 (en) | 2010-06-22 | 2019-11-12 | Primal Fusion Inc. | Methods and devices for customizing knowledge representation systems |
| CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
| CN105106200A (zh) * | 2011-05-17 | 2015-12-02 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
| CA2835927A1 (en) * | 2011-05-17 | 2012-11-22 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| GB201113662D0 (en) * | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
| ES2814336T3 (es) * | 2012-04-13 | 2021-03-26 | Glaxosmithkline Ip Dev Ltd | Partículas de agregado |
| SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
| CN102872027B (zh) * | 2012-09-18 | 2014-03-12 | 刘晓忠 | 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备 |
| EP2948148B1 (en) * | 2013-01-28 | 2020-07-29 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
| GB201301721D0 (en) * | 2013-01-31 | 2013-03-20 | Prosonix Ltd | Pharmaceutical Preparations |
| EP2950792A1 (en) | 2013-01-31 | 2015-12-09 | Prosonix Limited | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy |
| CA2901015A1 (en) * | 2013-03-04 | 2014-09-12 | Besins Healthcare Luxembourg Sarl | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles |
| CA2898700C (en) * | 2013-03-14 | 2022-07-19 | Novartis Ag | Deamorphization of spray-dried formulations via spray-blending |
| SG11201507286QA (en) | 2013-03-15 | 2015-10-29 | Pearl Therapeutics Inc | Methods and systems for conditioning of particulate crystalline materials |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| SG11201509543YA (en) * | 2013-05-22 | 2015-12-30 | Pearl Therapeutics Inc | Compositions, methods & systems for respiratory delivery of three or more active agents |
| CN105451716A (zh) | 2013-07-18 | 2016-03-30 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
| US20160243320A1 (en) * | 2013-10-07 | 2016-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder inhaler |
| CA2930170A1 (en) * | 2013-11-22 | 2015-05-28 | Teva Branded Pharmaceutical Products R&D, Inc. | An inhalable medicament |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| CN104188941B (zh) * | 2014-09-02 | 2016-11-16 | 重庆和平制药有限公司 | 一种制备盐酸克仑特罗吸入粉雾剂的方法 |
| CA2961660A1 (en) * | 2014-10-01 | 2016-04-07 | Als Mountain Llc | Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| WO2016170518A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| WO2017108917A1 (en) | 2015-12-22 | 2017-06-29 | Astrazeneca Ab | Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease |
| WO2017157265A1 (zh) * | 2016-03-15 | 2017-09-21 | 广东东阳光药业有限公司 | 喷雾剂、喷雾装置以及喷雾组件 |
| WO2017201003A1 (en) * | 2016-05-17 | 2017-11-23 | Mayo Foundation For Medical Education And Research | Materials and methods for treating chronic cough |
| KR102559152B1 (ko) | 2016-06-30 | 2023-07-26 | 필립모리스 프로덕츠 에스.에이. | 니코틴 입자 |
| PE20191043A1 (es) * | 2016-09-19 | 2019-08-06 | Mexichem Fluor Sa De Cv | Composicion farmaceutica |
| JP6906947B2 (ja) * | 2016-12-22 | 2021-07-21 | キヤノン株式会社 | 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| CN107243080B (zh) * | 2017-06-21 | 2021-11-12 | 上海上药信谊药厂有限公司 | 一种吸入式气雾剂、其原料组合物及制备方法 |
| IL273713B2 (en) * | 2017-10-09 | 2023-10-01 | Pearl Therapeutics Inc | Drug delivery systems and related methods |
| JP7372727B2 (ja) | 2017-11-20 | 2023-11-01 | 三菱重工業株式会社 | 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム |
| EP3860580A4 (en) * | 2018-10-01 | 2022-07-20 | Kindeva Drug Delivery L.P. | FORMULATION AND AEROSOL CARTRIDGES, INHALATORS AND THE LIKE CONTAINING THE FORMULATION |
| CN112789033A (zh) * | 2018-10-02 | 2021-05-11 | 学校法人名城大学 | 吸入粉末剂、其评价方法及其用途 |
| CN109632555B (zh) * | 2018-12-28 | 2021-07-27 | 上海新黄河制药有限公司 | 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法 |
| WO2020229966A1 (en) * | 2019-05-10 | 2020-11-19 | Glenmark Pharmaceutical Limited | Stable aerosol composition for inhalation comprising glycopyrronium |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| CN112804991B (zh) * | 2019-06-27 | 2022-03-11 | 广州谷森制药有限公司 | 含富马酸福莫特罗和阿地溴铵的可吸入溶液制剂 |
| CN112972384B (zh) * | 2019-12-02 | 2022-03-18 | 长风药业股份有限公司 | 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法 |
| JP2023513969A (ja) * | 2020-02-20 | 2023-04-04 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 緩衝化医薬製剤を含む加圧定量吸入器 |
| AU2021276611A1 (en) * | 2020-05-18 | 2022-12-15 | Orexo Ab | New pharmaceutical composition for drug delivery |
| US20220000767A1 (en) * | 2020-07-06 | 2022-01-06 | Sensory Cloud, Inc. | Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi |
| WO2022016068A1 (en) * | 2020-07-16 | 2022-01-20 | Tbd Pharma Llc | Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections |
| US11844793B2 (en) | 2020-09-29 | 2023-12-19 | Aerorx Therapeutics Llc | Liquid formulations of indacaterol |
| CN116710104A (zh) * | 2021-01-08 | 2023-09-05 | 江苏恒瑞医药股份有限公司 | 可通过定量吸入器递送的药物组合物 |
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| IL309888A (en) | 2021-07-09 | 2024-03-01 | Astrazeneca Pharmaceuticals Lp | Aerosol drug delivery compounds, methods and systems |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| JP2024541470A (ja) | 2021-11-25 | 2024-11-08 | オレクソ・アクチエボラゲット | アドレナリンを含む医薬組成物 |
| EP4452230A1 (en) | 2021-12-20 | 2024-10-30 | Astrazeneca AB | Compositions, methods and systems for aerosol drug delivery |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| WO2023212191A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
| WO2024206662A1 (en) * | 2023-03-30 | 2024-10-03 | Aerorx Therapeutics Llc | Liquid formulations of indacaterol and glycopyrronium |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| US20250268914A1 (en) * | 2024-02-26 | 2025-08-28 | Honeywell International Inc. | Fluticasone delivery compositions, devices and methods |
| CN118787617A (zh) * | 2024-09-14 | 2024-10-18 | 苏州易合医药有限公司 | 一种吸入粉剂及其制备方法 |
Family Cites Families (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4187301A (en) * | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| CA1201114A (en) * | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
| DE3260474D1 (en) | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8432063D0 (en) | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
| US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| FR2651678B1 (fr) | 1989-09-08 | 1992-04-30 | Glaxo Group Ltd | Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone. |
| US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| IE912999A1 (en) | 1990-09-07 | 1992-03-11 | Abbott Lab | Phenanthridine compounds |
| PL165803B1 (pl) | 1990-09-10 | 1995-02-28 | Schering Corp | Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL |
| DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| US5635563A (en) | 1991-04-01 | 1997-06-03 | Tomoegawa Paper Co., Ltd. | Polyaniline derivatives and their production process |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| WO1993011773A1 (en) | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5849263A (en) | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| WO1995015151A1 (en) | 1993-12-02 | 1995-06-08 | Abbott Laboratories | Aerosol drug formulations for use with non-cfc propellants |
| SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| JPH09508695A (ja) | 1994-02-09 | 1997-09-02 | キナートン・リミテッド | 溶液から材料を乾燥する方法 |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| DE69530325T2 (de) * | 1994-12-22 | 2004-02-19 | Astrazeneca Ab | Aerosol-arzneiformulierungen |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| GB9507768D0 (en) | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US6309671B1 (en) * | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| DE19614421C2 (de) | 1996-04-12 | 1999-12-16 | Biovision Gmbh | Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff |
| GB9610821D0 (en) | 1996-05-23 | 1996-07-31 | Glaxo Wellcome Inc | Metering apparatus |
| GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| US5886200A (en) | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US6068832A (en) * | 1996-08-29 | 2000-05-30 | Schering Corporation | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| DE59709927D1 (de) * | 1996-11-11 | 2003-05-28 | Noe Christian | Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| ATE284677T1 (de) | 1997-03-20 | 2005-01-15 | Schering Corp | Herstellung von pulveragglomeraten |
| US6129905A (en) * | 1997-04-21 | 2000-10-10 | Aeropharm Technology, Inc. | Aerosol formulations containing a sugar as a dispersant |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| DE69814428T2 (de) * | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| HUP0101733A3 (en) | 1998-03-05 | 2001-12-28 | Senju Pharma Co | Pharmaceutical compositions containing sulfonyl-dipeptides and their use |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| US6260549B1 (en) * | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
| US6451285B2 (en) * | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| ATE283033T1 (de) | 1998-07-24 | 2004-12-15 | Jago Res Ag | Medizinische aerosolformulierungen |
| EP1102579B1 (de) * | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| DK1131059T3 (da) * | 1998-11-13 | 2003-06-30 | Jago Res Ag | Tørpulver til inhalation |
| GB9912639D0 (en) * | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| NZ512383A (en) | 1998-12-22 | 2003-05-30 | Univ North Carolina | Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| EP1158958B1 (en) | 1999-03-05 | 2007-06-06 | CHIESI FARMACEUTICI S.p.A. | Improved powdery pharmaceutical compositions for inhalation |
| SE9900833D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| DK1169019T3 (da) | 1999-04-14 | 2003-06-02 | Glaxo Group Ltd | Farmaceutisk aerosolformulering |
| US20100197719A1 (en) * | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| TW453876B (en) | 1999-06-30 | 2001-09-11 | Inhale Therapeutic Syst | Spray drying process control of drying kinetics |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| NZ500555A (en) | 1999-08-02 | 2000-11-24 | Hovione Int Ltd | Process for the preparation of mometasone furoate |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| CN1188111C (zh) * | 1999-10-29 | 2005-02-09 | 耐科塔医药公司 | 分散性得到改进的干粉组合物 |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US20030026766A1 (en) | 2000-04-13 | 2003-02-06 | Mark Sanders | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| CA2382133C (en) * | 2000-05-10 | 2010-11-23 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| AU2000265583A1 (en) | 2000-08-15 | 2002-02-25 | Carsten Berg | Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| US20040081627A1 (en) * | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| DK2283818T3 (en) * | 2000-11-30 | 2017-10-16 | Vectura Ltd | Process for preparing particles for use in a pharmaceutical composition |
| DK1337240T4 (en) | 2000-11-30 | 2015-01-05 | Vectura Ltd | A process for the preparation of particles for use in a pharmaceutical composition |
| GB0029562D0 (en) | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| EP1345629A2 (en) | 2000-12-29 | 2003-09-24 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
| US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| ITMI20010428A1 (it) * | 2001-03-02 | 2002-09-02 | Chemo Breath S A | Composizioni ad uso inalatorio a base di formoterolo |
| US20040197271A1 (en) * | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
| DE50211045D1 (de) * | 2001-03-30 | 2007-11-22 | Jagotec Ag | Medizinische aerosolformulierungen |
| WO2002078761A1 (fr) * | 2001-03-30 | 2002-10-10 | Laboratoires Genevrier | Neo-tissu cartilagineux greffable |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| DE10202940A1 (de) * | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
| DE10214264A1 (de) | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen eines Anhydrats |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
| KR20060011783A (ko) * | 2002-06-12 | 2006-02-03 | 에피제네시스 파마슈티칼스 아이엔씨 | 데하이드로에피안드로스테론 스테로이드 및항-무스카린제와 더불어 호흡기 및 폐 질환을 치료하기위한 조성물, 제제 및 키트 |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| JP2005536538A (ja) | 2002-08-23 | 2005-12-02 | シェーリング コーポレイション | 薬学的組成物 |
| CN1694689A (zh) | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| US6942821B2 (en) * | 2002-10-15 | 2005-09-13 | Cryovac, Inc. | Process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger |
| EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| DE10323966A1 (de) | 2003-05-27 | 2004-12-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| MXPA05012821A (es) | 2003-05-28 | 2006-02-13 | Nektar Therapeutics | Formulacion farmaceutica que comprende un agente activo insoluble en agua. |
| US7238664B2 (en) * | 2003-06-16 | 2007-07-03 | Altana Pharma Ag | Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases |
| SE527190C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| CA2533791C (en) | 2003-07-28 | 2012-05-22 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
| RU2361586C2 (ru) | 2003-07-29 | 2009-07-20 | Берингер Ингельхайм Интернациональ Гмбх | Комбинация из антихолинергического средства и стероида и ее применение для лечения заболеваний дыхательных путей путем ингаляции |
| PT1651270E (pt) | 2003-07-29 | 2007-04-30 | Boehringer Ingelheim Int | Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico |
| CA2534120C (en) | 2003-07-31 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
| EP1925293A3 (en) | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| US9308199B2 (en) * | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| ES2329586T3 (es) * | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
| JP2007517069A (ja) * | 2003-12-31 | 2007-06-28 | サイデックス・インコーポレイテッド | スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤 |
| PT1713473E (pt) * | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
| DE602005007708D1 (de) | 2004-02-06 | 2008-08-07 | Meda Pharma Gmbh & Co Kg | Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen |
| WO2005077339A1 (en) | 2004-02-10 | 2005-08-25 | E.I. Dupont De Nemours And Company | Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| PL1765288T3 (pl) | 2004-06-18 | 2013-04-30 | Novartis Ag | Preparaty tobramycyny do leczenia zakażań oskrzeli |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| US20060140873A1 (en) | 2004-12-27 | 2006-06-29 | Chang Heng W | Aerosol pharmaceutical compositions |
| JP2008534480A (ja) | 2005-03-24 | 2008-08-28 | ソーセイ アールアンドディ リミテッド | グリコピロニウム塩およびそれらの治療的使用 |
| EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
| WO2006114379A1 (de) | 2005-04-23 | 2006-11-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EP1893203A2 (en) | 2005-05-31 | 2008-03-05 | Boehringer Ingelheim International GmbH | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
| CA2611907A1 (en) | 2005-06-17 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Mrp iv inhibitors for the treatment of respiratory diseases |
| AU2006272438B2 (en) | 2005-07-15 | 2011-08-04 | Map Pharmaceuticals, Inc. | Method of particle formation |
| EP1906919A4 (en) | 2005-07-15 | 2012-12-26 | Map Pharmaceuticals Inc | MULTIPLE ACTIVE PHARMACEUTICAL PRINCIPLES COMBINED IN DISCRETE INHALATION PARTICLES AND THEIR FORMULATIONS |
| CN100560598C (zh) * | 2005-07-26 | 2009-11-18 | 上海奥锐特国际贸易有限公司 | 氟替卡松丙酸酯的合成方法 |
| AT502396B1 (de) | 2005-09-01 | 2007-03-15 | Montanuniv Leoben | Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| NZ568349A (en) * | 2005-12-21 | 2011-05-27 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| US8263645B2 (en) * | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
| EP1981475A2 (en) * | 2006-02-09 | 2008-10-22 | Schering Corporation | Pharmaceutical formulations |
| JP2009537585A (ja) | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療のための新規医薬組成物 |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0614621D0 (en) * | 2006-07-24 | 2006-08-30 | 3M Innovative Properties Co | Metered dose dispensers |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| JP2010519195A (ja) * | 2007-02-19 | 2010-06-03 | シプラ・リミテッド | 薬学的組成物 |
| EP1964564A1 (en) * | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| EP2036572A1 (en) | 2007-09-04 | 2009-03-18 | Novo Nordisk A/S | Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle |
| CN101317821B (zh) * | 2007-11-15 | 2012-01-04 | 陈晓东 | 适用于肺部给药的超细干粉颗粒及其制备方法 |
| PT2234595E (pt) * | 2007-12-13 | 2013-01-24 | Novartis Ag | Processo para redução da tendência de um sal de glicopirrónio para se agregar durante a armazenagem |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| FR2940162B1 (fr) | 2008-12-22 | 2011-02-25 | Boehm & Cie Ets | Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension |
| WO2010097188A1 (en) | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| TWI792140B (zh) * | 2009-05-29 | 2023-02-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
| BR112012024059B1 (pt) | 2010-04-01 | 2021-06-01 | Chiesi Farmaceutici S.P.A. | Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco |
| EP2627317A4 (en) | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE |
| RU2013142268A (ru) | 2011-02-17 | 2015-03-27 | Сипла Лимитед | Фармацевтическая композиция |
| JO3510B1 (ar) | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| CA2835927A1 (en) | 2011-05-17 | 2012-11-22 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
| SG11201509543YA (en) | 2013-05-22 | 2015-12-30 | Pearl Therapeutics Inc | Compositions, methods & systems for respiratory delivery of three or more active agents |
-
2010
- 2010-05-28 TW TW110100317A patent/TWI792140B/zh active
- 2010-05-28 AU AU2010253770A patent/AU2010253770B9/en active Active
- 2010-05-28 JP JP2012513314A patent/JP5823383B2/ja active Active
- 2010-05-28 KR KR1020117028551A patent/KR101748892B1/ko active Active
- 2010-05-28 SI SI201031975T patent/SI3106149T1/sl unknown
- 2010-05-28 PL PL16164845T patent/PL3106149T3/pl unknown
- 2010-05-28 TW TW105116641A patent/TWI633898B/zh active
- 2010-05-28 BR BRPI1011229A patent/BRPI1011229B8/pt active IP Right Grant
- 2010-05-28 RU RU2016117972A patent/RU2016117972A/ru not_active Application Discontinuation
- 2010-05-28 LT LTEP10721258.1T patent/LT2435023T/lt unknown
- 2010-05-28 LT LTEP16164844.9T patent/LT3111926T/lt unknown
- 2010-05-28 AR ARP100101882A patent/AR076806A1/es not_active Application Discontinuation
- 2010-05-28 TW TW099117220A patent/TWI539979B/zh active
- 2010-05-28 SI SI201031263A patent/SI2435023T1/sl unknown
- 2010-05-28 HU HUE10727551A patent/HUE031229T2/en unknown
- 2010-05-28 JP JP2012513311A patent/JP5873012B2/ja active Active
- 2010-05-28 CA CA2763941A patent/CA2763941A1/en not_active Abandoned
- 2010-05-28 TW TW099117221A patent/TWI632926B/zh active
- 2010-05-28 LT LTEP16164849.8T patent/LT3111927T/lt unknown
- 2010-05-28 CN CN201710722981.4A patent/CN107669664B/zh active Active
- 2010-05-28 RU RU2015151358A patent/RU2713404C2/ru active
- 2010-05-28 RU RU2016107464A patent/RU2751771C2/ru active
- 2010-05-28 PL PL10727553T patent/PL2435025T3/pl unknown
- 2010-05-28 SI SI201031260A patent/SI2435024T1/sl unknown
- 2010-05-28 HU HUE10721258A patent/HUE031283T2/hu unknown
- 2010-05-28 PT PT161648456T patent/PT3106149T/pt unknown
- 2010-05-28 SM SM20200109T patent/SMT202000109T1/it unknown
- 2010-05-28 TW TW099117219A patent/TWI546094B/zh active
- 2010-05-28 DK DK16164849.8T patent/DK3111927T3/da active
- 2010-05-28 US US12/790,671 patent/US20110135737A1/en not_active Abandoned
- 2010-05-28 DK DK16164845.6T patent/DK3106149T3/da active
- 2010-05-28 CA CA2763939A patent/CA2763939A1/en not_active Abandoned
- 2010-05-28 MX MX2020004077A patent/MX393243B/es unknown
- 2010-05-28 AR ARP100101885A patent/AR076621A1/es not_active Application Discontinuation
- 2010-05-28 LT LTEP10727551.3T patent/LT2435024T/lt unknown
- 2010-05-28 MX MX2017011058A patent/MX377778B/es unknown
- 2010-05-28 MX MX2011012685A patent/MX350164B/es active IP Right Grant
- 2010-05-28 KR KR1020117028582A patent/KR20120015334A/ko not_active Ceased
- 2010-05-28 EP EP10727553.9A patent/EP2435025B1/en active Active
- 2010-05-28 WO PCT/US2010/036659 patent/WO2010138868A2/en not_active Ceased
- 2010-05-28 HR HRP20161098TT patent/HRP20161098T1/hr unknown
- 2010-05-28 DK DK10727553.9T patent/DK2435025T3/en active
- 2010-05-28 HU HUE16164845A patent/HUE047834T2/hu unknown
- 2010-05-28 LT LTEP10727553.9T patent/LT2435025T/lt unknown
- 2010-05-28 ME MEP-2020-37A patent/ME03631B/me unknown
- 2010-05-28 HR HRP20161102TT patent/HRP20161102T1/hr unknown
- 2010-05-28 TW TW107126090A patent/TWI695723B/zh active
- 2010-05-28 KR KR1020177016074A patent/KR20170070274A/ko not_active Ceased
- 2010-05-28 RU RU2011154083A patent/RU2580315C3/ru active Protection Beyond IP Right Term
- 2010-05-28 PT PT107212581T patent/PT2435023T/pt unknown
- 2010-05-28 BR BRPI1011220-0A patent/BRPI1011220B1/pt active IP Right Grant
- 2010-05-28 US US12/790,448 patent/US9463161B2/en active Active
- 2010-05-28 DK DK16164844.9T patent/DK3111926T3/da active
- 2010-05-28 WO PCT/US2010/036650 patent/WO2010138862A2/en not_active Ceased
- 2010-05-28 AU AU2010253776A patent/AU2010253776B2/en active Active
- 2010-05-28 DK DK10721258.1T patent/DK2435023T3/en active
- 2010-05-28 HR HRP20161101TT patent/HRP20161101T1/hr unknown
- 2010-05-28 EP EP10721258.1A patent/EP2435023B1/en active Active
- 2010-05-28 AR ARP100101884A patent/AR076807A1/es not_active Application Discontinuation
- 2010-05-28 KR KR1020177024590A patent/KR101926060B1/ko active Active
- 2010-05-28 HU HUE16164849A patent/HUE047823T2/hu unknown
- 2010-05-28 CN CN201610862606.5A patent/CN107412212B/zh active Active
- 2010-05-28 CN CN201080033312.2A patent/CN102753152B/zh active Active
- 2010-05-28 PT PT161648449T patent/PT3111926T/pt unknown
- 2010-05-28 WO PCT/US2010/036676 patent/WO2010138884A2/en not_active Ceased
- 2010-05-28 US US12/790,710 patent/US20110132357A1/en not_active Abandoned
- 2010-05-28 AU AU2010253950A patent/AU2010253950C1/en active Active
- 2010-05-28 PT PT107275513T patent/PT2435024T/pt unknown
- 2010-05-28 PL PL16164849T patent/PL3111927T3/pl unknown
- 2010-05-28 PL PL16164844T patent/PL3111926T3/pl unknown
- 2010-05-28 SI SI201031984T patent/SI3111927T1/sl unknown
- 2010-05-28 KR KR1020117028583A patent/KR101976107B1/ko active Active
- 2010-05-28 TW TW106115156A patent/TWI717511B/zh active
- 2010-05-28 PL PL10721258T patent/PL2435023T3/pl unknown
- 2010-05-28 BR BRPI1011508A patent/BRPI1011508A2/pt not_active Application Discontinuation
- 2010-05-28 CA CA2763936A patent/CA2763936C/en active Active
- 2010-05-28 ES ES16164849T patent/ES2774367T3/es active Active
- 2010-05-28 HU HUE16164844A patent/HUE047803T2/hu unknown
- 2010-05-28 PT PT161648498T patent/PT3111927T/pt unknown
- 2010-05-28 SM SM20200108T patent/SMT202000108T1/it unknown
- 2010-05-28 MX MX2011012684A patent/MX350163B/es active IP Right Grant
- 2010-05-28 CN CN201080033311.8A patent/CN102458364B/zh active Active
- 2010-05-28 EP EP16164849.8A patent/EP3111927B1/en active Active
- 2010-05-28 ES ES10721258.1T patent/ES2592536T3/es active Active
- 2010-05-28 CN CN201510450391.1A patent/CN105193773B/zh active Active
- 2010-05-28 DK DK10727551.3T patent/DK2435024T3/en active
- 2010-05-28 JP JP2012513319A patent/JP5873013B2/ja active Active
- 2010-05-28 ES ES16164844T patent/ES2774391T3/es active Active
- 2010-05-28 PL PL10727551T patent/PL2435024T3/pl unknown
- 2010-05-28 KR KR1020197012625A patent/KR20190049943A/ko not_active Ceased
- 2010-05-28 TW TW107143778A patent/TWI707700B/zh active
- 2010-05-28 US US12/790,605 patent/US8808713B2/en active Active
- 2010-05-28 ES ES10727553.9T patent/ES2593429T3/es active Active
- 2010-05-28 SI SI201031985T patent/SI3111926T1/sl unknown
- 2010-05-28 ES ES16164845T patent/ES2772253T3/es active Active
- 2010-05-28 ES ES10727551.3T patent/ES2589135T3/es active Active
- 2010-05-28 EP EP16164845.6A patent/EP3106149B1/en active Active
- 2010-05-28 MX MX2011012783A patent/MX337126B/es active IP Right Grant
- 2010-05-28 SI SI201031262A patent/SI2435025T1/sl unknown
- 2010-05-28 LT LTEP16164845.6T patent/LT3106149T/lt unknown
- 2010-05-28 EP EP10727551.3A patent/EP2435024B1/en active Active
- 2010-05-28 KR KR1020187034755A patent/KR20180130602A/ko not_active Abandoned
- 2010-05-28 SM SM20200077T patent/SMT202000077T1/it unknown
- 2010-05-28 CN CN201080033310.3A patent/CN102596176B/zh active Active
- 2010-05-28 HU HUE10727553A patent/HUE029532T2/en unknown
- 2010-05-28 EP EP16164844.9A patent/EP3111926B1/en active Active
- 2010-05-28 TW TW105111487A patent/TWI646980B/zh active
- 2010-05-28 PT PT107275539T patent/PT2435025T/pt unknown
-
2011
- 2011-11-10 ZA ZA2011/08275A patent/ZA201108275B/en unknown
- 2011-11-20 IL IL216466A patent/IL216466B/en active IP Right Grant
- 2011-11-20 IL IL216468A patent/IL216468B/en active IP Right Grant
- 2011-11-20 IL IL216467A patent/IL216467B/en active IP Right Grant
-
2012
- 2012-10-26 ZA ZA2012/08101A patent/ZA201208101B/en unknown
- 2012-10-26 ZA ZA2012/08100A patent/ZA201208100B/en unknown
- 2012-10-26 ZA ZA2012/08102A patent/ZA201208102B/en unknown
-
2014
- 2014-07-09 US US14/327,425 patent/US20150017247A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084240A patent/JP6189356B2/ja active Active
- 2015-04-16 JP JP2015084226A patent/JP6169639B2/ja active Active
- 2015-10-07 JP JP2015199079A patent/JP2016041713A/ja not_active Withdrawn
-
2016
- 2016-04-21 US US15/135,389 patent/US20170071850A1/en not_active Abandoned
- 2016-08-30 US US15/252,001 patent/US20170112759A1/en not_active Abandoned
- 2016-09-20 SM SM201600326T patent/SMT201600326B/it unknown
- 2016-09-20 SM SM201600327T patent/SMT201600327B/it unknown
- 2016-09-21 CY CY20161100939T patent/CY1118040T1/el unknown
- 2016-09-21 CY CY20161100940T patent/CY1118034T1/el unknown
- 2016-09-21 CY CY20161100941T patent/CY1118030T1/el unknown
- 2016-09-21 SM SM201600329T patent/SMT201600329B/it unknown
-
2017
- 2017-04-26 PH PH12017500778A patent/PH12017500778A1/en unknown
- 2017-06-15 US US15/624,597 patent/US20180125776A1/en not_active Abandoned
- 2017-06-28 JP JP2017125969A patent/JP6492124B2/ja active Active
- 2017-08-02 JP JP2017149555A patent/JP6348645B2/ja active Active
- 2017-09-28 JP JP2017188628A patent/JP2018048150A/ja active Pending
-
2018
- 2018-02-16 US US15/932,249 patent/US20190038548A1/en not_active Abandoned
- 2018-11-02 US US16/179,712 patent/US10716753B2/en active Active
-
2019
- 2019-03-04 JP JP2019038501A patent/JP6876734B2/ja active Active
- 2019-06-06 CY CY2019031C patent/CY2019031I1/el unknown
- 2019-06-12 FR FR19C1040C patent/FR19C1040I2/fr active Active
- 2019-06-12 HU HUS1900031C patent/HUS1900031I1/hu unknown
- 2019-06-12 LU LU00124C patent/LUC00124I2/fr unknown
- 2019-06-13 NO NO2019026C patent/NO2019026I1/no unknown
- 2019-06-14 NL NL300995C patent/NL300995I2/nl unknown
- 2019-06-17 LT LTPA2019014C patent/LTC2435025I2/lt unknown
-
2020
- 2020-01-24 RU RU2020102859A patent/RU2020102859A/ru unknown
- 2020-01-31 HR HRP20200166TT patent/HRP20200166T1/hr unknown
- 2020-02-14 CY CY20201100136T patent/CY1122749T1/el unknown
- 2020-02-17 HR HRP20200260TT patent/HRP20200260T1/hr unknown
- 2020-02-21 HR HRP20200298TT patent/HRP20200298T1/hr unknown
- 2020-02-25 CY CY20201100173T patent/CY1122732T1/el unknown
- 2020-02-28 CY CY20201100185T patent/CY1122807T1/el unknown
- 2020-08-03 US US16/983,543 patent/US20210186861A1/en not_active Abandoned
-
2021
- 2021-05-10 CY CY2021012C patent/CY2021012I2/el unknown
- 2021-05-12 NO NO2021019C patent/NO2021019I1/no unknown
- 2021-05-12 HU HUS2100018C patent/HUS2100018I1/hu unknown
- 2021-05-19 LU LU00208C patent/LUC00208I2/fr unknown
- 2021-06-04 LT LTPA2021511C patent/LTC2435024I2/lt unknown
-
2024
- 2024-02-20 US US18/582,344 patent/US20250009652A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528200A5 (enExample) | ||
| US20250009652A1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| JP2012528792A5 (enExample) | ||
| JP2012528199A5 (enExample) | ||
| JP2016041713A5 (enExample) | ||
| US20150150787A1 (en) | Compositions, methods & systems for respiratory delivery of three or more active agents | |
| PT1480615E (pt) | Formulação superfina de formoterol | |
| ES2983201T3 (es) | Composiciones, métodos y sistemas para la administración de fármacos en aerosol | |
| TWI436761B (zh) | 使用噻唑衍生物之方法 | |
| US20250057764A1 (en) | Compositions, methods and systems for aerosol drug delivery | |
| AU2019203814A1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| HK1228797A1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| HK1228797A (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| HK1228797B (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| JPWO2023119093A5 (enExample) |